Erschienen in:
25.01.2024 | ASO Author Reflections
ASO Author Reflections: What Can Prediction Models for Upstaging of DCIS Diagnosed on Biopsy Tell Us About DCIS Surveillance Trials?
verfasst von:
Pieter Westenend, MD, PhD, Claudia Meurs, MS, Sara van Bekkum, MD, Joost van Rosmalen, PhD, Marian Menke-Pluijmers, MD, PhD, Sabine Siesling, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 4/2024
Einloggen, um Zugang zu erhalten
Excerpt
Since not all ductal carcinoma in situ (DCIS) will progress to invasive breast cancer (IBC), surgery may be considered overtreatment in some cases. Reducing overtreatment is the rationale behind ongoing surveillance trials for DCIS.
1‐3 In these trials, selection of patients with low risk of progression is critical. …